Georges Noel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9552173/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quality control of 3D MRSI data in glioblastoma: Can we do without the experts?. Magnetic Resonance in Medicine, 2022, 87, 1688-1699.	3.0	5
2	Delineation of organs at risk. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 76-91.	1.4	2
3	The Impact of an Incidental Dose on Axillary Tumor Control and Toxicity in Localized Breast Cancer: A Retrospective Analysis. Cancers, 2022, 14, 807.	3.7	2
4	Management of metallic implants in radiotherapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 411-416.	1.4	0
5	Radiation therapy for brain metastases. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 129-136.	1.4	6
6	Increased cardiac uptake of (18F)-fluorodeoxyglucose incidentally detected on positron emission tomography after left breast irradiation: How to interpret?. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 724-729.	1.4	2
7	Organs at risk radiation dose constraints. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 59-75.	1.4	29
8	Radiation guidelines for gliomas. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 116-128.	1.4	3
9	Evaluation of Microscopic Tumour Extension in Localized Stage Non-Small-Cell Lung Cancer for Stereotactic Radiotherapy Planning. Cancers, 2022, 14, 1282.	3.7	0
10	Local recurrence and cerebral progression-free survival after multiple sessions of stereotactic radiotherapy of brain metastases: aÂretrospective study of 184Âpatients. Strahlentherapie Und Onkologie, 2022, 198, 527-536.	2.0	6
11	Radionecrosis after repeated courses of radiotherapy under stereotactic conditions for brain metastases: Analysis of clinical and dosimetric data from a retrospective cohort of 184 patients. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 692-702.	1.4	4
12	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Critical Reviews in Oncology/Hematology, 2021, 157, 103188.	4.4	17
13	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 – Radiological features and metric markers. Critical Reviews in Oncology/Hematology, 2021, 159, 103230.	4.4	32
14	Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers, 2021, 13, 2394.	3.7	6
15	A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value. Cancers, 2021, 13, 2252.	3.7	2
16	Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines. International Journal of Molecular Sciences, 2021, 22, 6825.	4.1	8
17	Role of hippocampal location and radiation dose in glioblastoma patients with hippocampal atrophy. Radiation Oncology, 2021, 16, 112.	2.7	5
18	Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes. Frontiers in Immunology, 2021, 12, 636108.	4.8	6

#	Article	IF	CITATIONS
19	Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review. Cancers, 2021, 13, 3623.	3.7	8
20	Incidental axillary dose delivery to axillary lymph node levelsÂl–III by different techniques of whole-breast irradiation: aÂsystematic literature review. Strahlentherapie Und Onkologie, 2021, 197, 820-828.	2.0	9
21	Proton Therapy and Gliomas: A Systematic Review. Radiation, 2021, 1, 218-233.	1.4	10
22	Interpretable Machine Learning Model for Locoregional Relapse Prediction in Oropharyngeal Cancers. Cancers, 2021, 13, 57.	3.7	13
23	Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study. Frontiers in Oncology, 2021, 11, 781121.	2.8	1
24	Clinical and epidemiological observations on individual radiation sensitivity and susceptibility. International Journal of Radiation Biology, 2020, 96, 324-339.	1.8	35
25	Kiâ€67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, <i>IDH1</i> â€mutant and 1p/19qâ€codeleted: a multicenter study from the French POLA network. Brain Pathology, 2020, 30, 465-478.	4.1	20
26	Radiographic findings after stereotactic body radiation therapy for stage I non-small cell lung carcinomas: retrospective analysis of 90 patients. Journal of Radiotherapy in Practice, 2020, 19, 333-340.	0.5	0
27	Role of radiation therapy in brain metastases management. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 463-469.	1.4	10
28	Internal mammary and medial supraclavicular lymph node chain irradiation in stage l–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1602-1610.	10.7	164
29	The Cryo-immunologic effect: A therapeutic advance in the treatment of glioblastomas?. Neurochirurgie, 2020, 66, 455-460.	1.2	3
30	Sensitivity of the Montreal Cognitive Assessment in screening for cognitive impairment in patients with newly diagnosed high-grade glioma. Journal of Neuro-Oncology, 2020, 148, 335-342.	2.9	5
31	Brain metastasis formation and irradiation by stereotactic radiation therapy combined with immunotherapy: A systematic review. Critical Reviews in Oncology/Hematology, 2020, 149, 102923.	4.4	12
32	Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis. Chinese Clinical Oncology, 2020, 9, 55-55.	1.2	1
33	Targeting DNA repair in combination with radiotherapy in pancreatic cancer: A systematic review of preclinical studies. Critical Reviews in Oncology/Hematology, 2020, 153, 103060.	4.4	5
34	Radiation-induced lung toxicity predictors: Retrospective analysis of 90 patients treated with stereotactic body radiation therapy for stage I non-small-cell lung carcinoma. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 120-127.	1.4	7
35	Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. Frontiers in Oncology, 2020, 10, 613089.	2.8	4
36	A critical narrative review of radiotherapy for retroperitoneal soft tissue sarcoma. Chinese Clinical Oncology, 2020, 9, 79-79.	1.2	5

#	Article	IF	CITATIONS
37	Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study. Journal of Neuro-Oncology, 2019, 144, 419-426.	2.9	10
38	Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report. Journal of Medical Case Reports, 2019, 13, 202.	0.8	6
39	Ability to Propose Optimal Prosthetic Rehabilitation can be Improved by Discussion between the Dentist and Radiation Oncologist Regarding Upstream Dosimetry. European Journal of Dentistry, 2019, 13, 088-094.	1.7	2
40	Efficacy and Tolerance of Intensity Modulated Radiation Therapy for Skull Base Meningioma. Advances in Radiation Oncology, 2019, 4, 587-595.	1.2	2
41	18F-FDOPA PET/CT Combined with MRI for Gross Tumor Volume Delineation in Patients with Skull Base Paraganglioma. Cancers, 2019, 11, 54.	3.7	7
42	Efficacy and toxicity of proton with photon radiation for locally advanced nasopharyngeal carcinoma. Acta OncolA ³ gica, 2019, 58, 472-474.	1.8	14
43	<p>Medulloblastoma: optimizing care with a multidisciplinary approach</p> . Journal of Multidisciplinary Healthcare, 2019, Volume 12, 335-347.	2.7	47
44	Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Cancer Epidemiology, 2019, 61, 89-94.	1.9	31
45	Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature. World Journal of Surgical Oncology, 2019, 17, 70.	1.9	4
46	An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients. Metabolomics, 2019, 15, 69.	3.0	5
47	RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study. EBioMedicine, 2019, 41, 420-426.	6.1	12
48	Intracranial Solitary Fibrous Tumors: A Heterogeneous Entity with an Uncertain Clinical Behavior. World Neurosurgery, 2019, 126, e48-e56.	1.3	24
49	Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. BMC Cancer, 2019, 19, 167.	2.6	39
50	IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. Neuro-Oncology, 2018, 20, 716-718.	1.2	8
51	A systematic review of palliative bone radiotherapy based on pain relief and retreatment rates. Critical Reviews in Oncology/Hematology, 2018, 123, 132-137.	4.4	17
52	Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review. Critical Reviews in Oncology/Hematology, 2018, 123, 138-148.	4.4	106
53	Multidisciplinary management of an intra-sellar cavernous hemangioma: Case report and review of the literature. Journal of Clinical Neuroscience, 2018, 52, 135-138.	1.5	17
54	Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 980-986.	0.8	10

#	Article	IF	CITATIONS
55	Comment on "Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgeryâ€, by Yang WC et al Radiotherapy and Oncology, 2018, 129, 187.	0.6	0
56	Proton beam therapy for skull base chordomas in 106 patients: A dose adaptive radiation protocol. Radiotherapy and Oncology, 2018, 128, 198-202.	0.6	48
57	Metastatic mediastinal mature teratoma with malignant transformation in a young man with an adenocarcinoma in a Klinefelter's syndrome: Case report and review of the literature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 255-263.	1.4	5
58	Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiotherapy and Oncology, 2018, 128, 534-540.	0.6	21
59	Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. Journal of Neuro-Oncology, 2018, 136, 565-576.	2.9	47
60	Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial. Oncotarget, 2018, 9, 15757-15765.	1.8	11
61	Stereotactic body radiation therapy for stage I non-small cell lung carcinomas: Moderate hypofractionation optimizes outcome. Lung Cancer, 2018, 126, 201-207.	2.0	9
62	Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. Oncologist, 2018, 23, 1500-1510.	3.7	6
63	Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. Radiotherapy and Oncology, 2018, 129, 520-526.	0.6	37
64	Factors improving the outcome of patients re-irradiated with intensity-modulated radiotherapy (IMRT) for relapse or new head and neck cancer developed in irradiated areas. Chinese Clinical Oncology, 2018, 7, 60-60.	1.2	6
65	Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 55-59.	1.4	15
66	Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. AÂretrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). European Journal of Cancer, 2017, 79, 119-128.	2.8	45
67	Stereotactic radiation therapy of brain metastases from colorectal cancer: A single institution cohort. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 199-204.	1.4	8
68	Le lymphome de hodgkin du sinus maxillaire, un piège diagnostique�. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2017, 134, 60-62.	0.0	0
69	Hypofractionated Stereotactic Radiation Therapy to the Resection Bed for Intracranial Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1179-1189.	0.8	66
70	Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?. Journal of Neuro-Oncology, 2017, 135, 285-297.	2.9	35
71	Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. Annals of Oncology, 2017, 28, 2962-2976.	1.2	57
72	Surgery Is an Effective Option after Failure of Chemoradiation in Cancers of the Anal Canal and Anal Margin. Oncology, 2017, 93, 183-190.	1.9	11

#	Article	IF	CITATIONS
73	Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score–Weighted Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 929-937.	0.8	23
74	Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases. Radiation Oncology, 2017, 12, 32.	2.7	1
75	Hodgkin lymphoma of the maxillary sinus: A diagnostic trap?. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2017, 134, 47-48.	0.7	4
76	A concurrent ultraâ€fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. International Journal of Cancer, 2016, 138, 1538-1544.	5.1	5
77	Investigation of ectopic recurrent skull base and cervical chordomas: The Institut Curie's proton therapy center experience. Head and Neck, 2016, 38, E1238-46.	2.0	8
78	Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 282-291.	1.4	11
79	Treatment that follows guidelines closely dramatically improves overall survival of patients with anal canal and margin cancers. Critical Reviews in Oncology/Hematology, 2016, 101, 131-138.	4.4	11
80	Implementing radiotherapy in Africa: Focus on the needs in Rwanda. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 231-235.	1.4	4
81	Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. Journal of Neuro-Oncology, 2016, 129, 85-92.	2.9	37
82	Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. Radiotherapy and Oncology, 2016, 120, 156-162.	0.6	8
83	Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 654-662.	0.8	19
84	Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?. Journal of Neuro-Oncology, 2016, 130, 181-192.	2.9	20
85	Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 357-361.	1.4	9
86	Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 794-800.	1.4	11
87	Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry. Reports of Practical Oncology and Radiotherapy, 2016, 21, 427-434.	0.6	6
88	A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 193-198.	1.4	8
89	Efficacy and Safety of Adjuvant Proton Therapy Combined With Surgery for Chondrosarcoma of the Skull Base: A Retrospective, Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 312-321.	0.8	63
90	Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients. Radiotherapy and Oncology, 2016, 118, 9-15.	0.6	34

#	Article	IF	CITATIONS
91	Impact of <i>EGFR</i> mutations and <i>KRAS</i> amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. Future Oncology, 2016, 12, 59-70.	2.4	34
92	Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation. European Radiology, 2016, 26, 4194-4203.	4.5	18
93	Maxillary and mandible contouring in patients with a head and neck area irradiation. Practical Radiation Oncology, 2016, 6, e61-e72.	2.1	7
94	Proton therapy for tumors of the base of the skull. Chinese Clinical Oncology, 2016, 5, 51-51.	1.2	29
95	Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. EBioMedicine, 2015, 2, 1965-1973.	6.1	87
96	Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture. Oncology Reports, 2015, 33, 471-477.	2.6	4
97	EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients. BMC Neurology, 2015, 15, 261.	1.8	17
98	Cognitive outcome after radiotherapy in brain tumor. Current Opinion in Oncology, 2015, 27, 510-515.	2.4	37
99	A high lymph node ratio predicts loco-regional recurrence while microscopic N2 predicts survival after radiation therapy in pIIIA-N2 non-small cell lung cancer. Journal of Radiation Oncology, 2015, 4, 169-176.	0.7	1
100	Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adhesion and Migration, 2015, 9, 141-153.	2.7	54
101	Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. Neuro-Oncology, 2015, 17, 1609-1619.	1.2	60
102	Three-Dimensional Cell Culture: A Breakthrough in Vivo. International Journal of Molecular Sciences, 2015, 16, 5517-5527.	4.1	709
103	Gene Expression Mapping of Histone Deacetylases and Co-factors and Correlation with Survival Time and 1H-HRMAS Metabolomic Profile in Human Gliomas. Scientific Reports, 2015, 5, 9087.	3.3	28
104	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology, 2015, 85, 1325-1331.	1.1	34
105	An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity. Current Cancer Drug Targets, 2015, 15, 624-640.	1.6	9
106	Secondary School Students' Knowledge of Physical Therapy: The Trinidadian Scenario. West Indian Medical Journal, 2014, 63, 151-8.	0.4	0
107	Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients. Radiation Oncology, 2014, 9, 259.	2.7	6
108	3D Radiation Therapy Boost Improves the Outcome of Whole Brain Radiation Therapy Treated RPA II Patients with One or Two Brain Metastases. International Journal of Molecular Sciences, 2014, 15, 7554-7562.	4.1	6

#	Article	IF	CITATIONS
109	Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer. Ecological Management and Restoration, 2014, 27, 560-567.	0.4	52
110	Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro-Oncology, 2014, 16, 1244-1254.	1.2	47
111	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro-Oncology, 2014, 16, 662-670.	1.2	59
112	Age impacts the pattern of care for elderly patients with rectal cancer. International Journal of Colorectal Disease, 2014, 29, 157-163.	2.2	20
113	An Emulsion Restores the Skin Barrier by Decreasing the Skin pH and Inflammation in a Canine Experimental Model. Journal of Comparative Pathology, 2014, 151, 244-254.	0.4	14
114	Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease. Radiation Oncology, 2013, 8, 112.	2.7	15
115	Early evaluation predicts pain relief of irradiated bone metastases: a single-center prospective study. BMC Palliative Care, 2013, 12, 12.	1.8	8
116	Institutional, Retrospective Analysis of 777 Patients With Brain Metastases: Treatment Outcomes and Diagnosis-Specific Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2013, 86, 630-637.	0.8	25
117	CD8â€alpha Tâ€cell infiltration in human papillomavirusâ€related oropharyngeal carcinoma correlates with improved patient prognosis. International Journal of Cancer, 2013, 132, E26-36.	5.1	82
118	Impact of 3D Conformal Radiotherapy on Lung Function of Patients with Lung Cancer: A Prospective Study. Respiration, 2013, 86, 100-108.	2.6	12
119	A retrospective outcome study in the elder patient with locally advanced rectal cancer treated with hypofractionated or conventional preoperative radiotherapy. Journal of Solid Tumors, 2013, 3, .	0.1	1
120	Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy. Cancers, 2013, 5, 1177-1198.	3.7	16
121	Outcome Improvement in RPA I or II Patients With 1 or 2 Brain Metastases by Combined Surgery and Radiotherapy. World Journal of Oncology, 2013, 4, 37-45.	1.5	3
122	An Institutional Retrospective Analysis of 93 Patients with Brain Metastases from Breast Cancer: Treatment Outcomes, Diagnosis-Specific Prognostic Factors. International Journal of Molecular Sciences, 2012, 13, 16489-16499.	4.1	10
123	The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy. International Journal of Oncology, 2012, 41, 1381-1386.	3.3	25
124	The NEDD8 conjugation pathway regulates p53 transcriptional activity and head and neck cancer cell sensitivity to ionizing radiation. International Journal of Oncology, 2012, 41, 1531-1540.	3.3	22
125	Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas. International Journal of Radiation Oncology Biology Physics, 2012, 82, 749-755	0.8	65
126	Comparison of the dosimetries of 3-dimensions Radiotherapy (3D-RT) with linear accelerator and intensity modulated radiotherapy (IMRT) with helical tomotherapy in children irradiated for neuroblastoma. BMC Medical Physics, 2012, 12, 2.	2.4	9

#	Article	IF	CITATIONS
127	Can exhaled NO fraction predict radiotherapy-induced lung toxicity in lung cancer patients?. Radiation Oncology, 2012, 7, 117.	2.7	8
128	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. PLoS ONE, 2012, 7, e45950.	2.5	25
129	Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. Journal of Neuro-Oncology, 2012, 109, 167-175.	2.9	51
130	Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncológica, 2011, 50, 477-478.	1.8	31
131	514 oral ORION(r): SIMPLE AND EFFECTIVE METHOD FOR SYSTEMIC ANALYSIS OF EVENT OCCURRING IN HOSPITAL PRACTICE. Radiotherapy and Oncology, 2011, 99, S209.	0.6	1
132	Comparison of time taken from initial presentation to histological diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United Kingdom and Strasbourg, France. Clinical Neurology and Neurosurgery, 2011, 113, 358-361.	1.4	4
133	Radiobiological Characterization of Two Therapeutic Proton Beams With Different Initial Energy Spectra Used at the Institut Curie Proton Therapy Center in Orsay. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1136-1143.	0.8	70
134	A Retrospective Analysis of 382 Patients with Brain Metastases: Overall Survival and Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2011, 81, S304.	0.8	1
135	Combined Proton and Photon Conformal Radiotherapy for Intracranial Atypical and Malignant Meningioma. International Journal of Radiation Oncology Biology Physics, 2009, 75, 399-406.	0.8	144
136	Proton Therapy in Pediatric Skull Base and Cervical Canal Low-Grade Bone Malignancies. International Journal of Radiation Oncology Biology Physics, 2008, 71, 672-675.	0.8	67
137	A Treatment Planning Comparison of Combined Photon–Proton Beams Versus Proton Beams–Only for the Treatment of Skull Base Tumors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 944-954.	0.8	40
138	Conformity index: A review. International Journal of Radiation Oncology Biology Physics, 2006, 64, 333-342.	0.8	741
139	Proton beam radiotherapy for uveal melanoma: Results of Curie Institut–Orsay Proton Therapy Center (ICPO). International Journal of Radiation Oncology Biology Physics, 2006, 65, 780-787.	0.8	205
140	Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1412-1422.	0.8	72
141	Linac stereotactic radiosurgery: An effective and safe treatment for elderly patients with brain metastases. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1555-1561.	0.8	53
142	Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncológica, 2005, 44, 700-708.	1.8	213
143	Chondrosarcomas of the base of the skull in Ollier's disease or Maffucci's syndrome Three Case Reports and Review of the Literature. Acta Oncológica, 2004, 43, 705-710.	1.8	34
144	LINAC radiosurgery for brain metastasis of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 25-31.	1.6	71

#	Article	IF	CITATIONS
145	Radiotherapeutic Factors in the Management of Cervical-basal Chordomas and Chondrosarcomas. Neurosurgery, 2004, 55, 1252-1262.	1.1	107
146	Radiation Therapy for Chordoma and Chondrosarcoma of the Skull Base and the Cervical Spine. Strahlentherapie Und Onkologie, 2003, 179, 241-248.	2.0	159
147	Radiosurgery for brain metastasis: impact of CTV on local control. Radiotherapy and Oncology, 2003, 68, 15-21.	0.6	80
148	Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer. Lung Cancer, 2003, 41, 333-343.	2.0	64
149	Predictive Factors of Radiation Necrosis after Radiosurgery for Cerebral Metastases. Stereotactic and Functional Neurosurgery, 2003, 81, 115-119.	1.5	38
150	Linac Radiosurgery for Brain Metastasis of Melanoma. Stereotactic and Functional Neurosurgery, 2002, 79, 245-255.	1.5	38
151	Highly Conformal Therapy Using Proton Component in the Management of Meningiomas. Strahlentherapie Und Onkologie, 2002, 178, 480-485.	2.0	50
152	Radiosurgery for re-irradiation of brain metastasis: results in 54 patients. Radiotherapy and Oncology, 2001, 60, 61-67.	0.6	91
153	Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie D'Orsay experience. International Journal of Radiation Oncology Biology Physics, 2001, 51, 392-398.	0.8	129